FDA HRT Update

What We’ve Learned Since 2002

For many women, hormone replacement therapy (HRT) has long been surrounded by confusion and conflicting information. Much of that uncertainty can be traced back to the Women’s Health Initiative (WHI) study published in 2002. The initial findings received widespread media attention and led millions of women to discontinue hormone therapy or avoid it altogether. However, researchers have spent more than two decades reexamining the data, and today’s scientific understanding is far more nuanced.

The original WHI study included many women who were significantly older than the average woman beginning menopause—most participants were in their 60s, and many started hormone therapy more than 10 years after menopause. Subsequent research has shown that age and timing matter significantly.

Current evidence indicates that healthy women who begin hormone therapy before age 60 or within 10 years of menopause often have a very different benefit-risk profile than women who start treatment later in life. This concept has become one of the most important advances in menopause medicine.

A New Era of Evidence-Based Care

In 2025, the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) announced actions to update hormone therapy labeling and patient information to better reflect current scientific evidence. These updates recognize that earlier warnings did not adequately distinguish between women beginning therapy near menopause and those initiating treatment many years later.

We follow a clinically rigorous, research‑driven bioidentical hormone therapy approach built on decades of published medical literature and physiology‑based dosing. This method is structured, standardized, and grounded in evidence—not templates or one‑size‑fits‑all protocols.

Our approach emphasizes:

Published research — guided by extensive peer‑reviewed data

Physiologic restoration — aiming for healthy, youthful hormone ranges

Individualized care — tailored to symptoms, labs, and menopausal stage

Whole‑system balance — addressing all major hormone pathways

Safety integration — cardiovascular, cognitive, bone, and metabolic review

Core clinical principles include:

Optimize rather than simply replace

Use bioidentical hormones for precise receptor compatibility

Evaluate symptoms and labs together

Balance hormones as an interconnected system

Maintain structured monitoring and follow‑up

Keep safety at the center of every decision

The “Window of Opportunity”

Bioidentical Hormone Replacement Therapy (BHRT) may also help support:

Healthy bones and reduced fracture risk

Heart and cardiovascular

Brain and cognitive function

Better sleep

Improved mood and emotional well-being

Vaginal and urinary health

Sexual wellness and libido

Energy, vitality, and overall quality of life

For many healthy women experiencing bothersome menopausal symptoms, hormone therapy remains the most effective treatment for hot flashes, night sweats, and other vasomotor symptoms.

Our Customized HRT Process

Practitioner reviews your health history
Hormonal Panels run for objective data
Symptoms ranked for subjective data
One-on-one practioner consult with client for full evaluation of all markers
Practitioner develops a personalized hormone optimization plan
Pharmaceutical products are dispensed to the client’s specific deficiencies
Symptoms are monitored by practitioner, dosing is adjusted as necessary

The goal isn’t simply to treat menopause—It’s to help you feel vibrant, healthy, and confident throughout every stage of life.